Compare SAP SE (SAP) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SAP SE vs State Street SPDR S&P Biotech ETF — how do they compare? SAP SE trades at $214.86 (market cap $238.67B), while State Street SPDR S&P Biotech ETF trades at $153.81 (market cap $10.11B). The key difference: SAP SE is far larger — about 23.6× State Street SPDR S&P Biotech ETF's market cap, and SAP SE pays a 1.38% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold SAP SE for 118 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| SAP | XBI | |
|---|---|---|
Market Cap | $238.67B | $10.11B |
Volume | 2,252,662 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $280.46 | $169.55 |
52-Week Low | $146.38 | $104.99 |
Typical Hold Time | 118 Days | 38 Days |
Enterprise Value | $237.42B | — |
Dividend Yield | 1.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SAP trades at $214.78, up 2.21% today, with a bullish technical signal and strong analyst consensus. Revenue grew to $36.80B in 2025, with net income of $7.16B and a robust 20.41% net margin. Recent earnings show mixed results, beating in Q4 2025 and Q1 2026 but missing in Q2 2026. The stock is supported by solid cash flow from operations of $9.16B and a healthy balance sheet with $11.24B in cash.
Outlook is positive with a consensus price target of $253.40, implying 18% upside. Risks include competitive pressures from AI-native startups and execution challenges in cloud margin expansion. Institutional sentiment remains bullish, with 51% of analysts rating it a buy, though near-term volatility may persist amid market hesitancy on 2027 projections.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
